Aspire Biopharma Holdings (ASBP) Non Operating Income (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has 5 years of Non Operating Income data on file, last reported at -$1.6 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 309.7% year-over-year to -$1.6 million in Q1 2026; TTM through Mar 2026 was -$6.3 million, a 3435.18% decrease from a year earlier, with the FY2025 full-year figure at -$5.1 million, down 5134.88% from the prior year.
• Non Operating Income for Q1 2026 stood at -$1.6 million, up from -$2.9 million in the prior quarter.
• Over the last five years, Non Operating Income for ASBP reached as high as $3.2 million in Q1 2023 and fell as low as -$2.9 million in Q4 2025.
• Historically, Non Operating Income has averaged $224592.1 across 5 years, with a median of $55577.0 in 2024.
• Across the five-year window, Non Operating Income jumped 14844.13% in 2023 and plunged 1066.86% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $2.5 million in 2022, then plunged by 90.11% to $251702.0 in 2023, then sank by 140.22% to -$101246.0 in 2024, then slumped by 2723.13% to -$2.9 million in 2025, then jumped by 44.84% to -$1.6 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were -$1.6 million in Q1 2026, -$2.9 million in Q4 2025, and -$704996.0 in Q3 2025.